# Induction Chemo-Nivo in Unresectable Stage III NSCLC

> **NCT06003075** · PHASE2 · TERMINATED · sponsor: **Ralph G Zinner** · enrollment: 1 (actual)

## Conditions studied

- Lung Cancer, Nonsmall Cell
- Lung Cancer Stage III

## Interventions

- **COMBINATION_PRODUCT:** Nivolumab and Chemotherapy
- **DRUG:** Nivolumab
- **PROCEDURE:** Post Induction Surgery
- **RADIATION:** Post Induction XRT

## Key facts

- **NCT ID:** NCT06003075
- **Lead sponsor:** Ralph G Zinner
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-13
- **Primary completion:** 2024-07-05
- **Final completion:** 2024-07-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003075, "Induction Chemo-Nivo in Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06003075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*